Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Transl Oncol ; 21(12): 1634-1643, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30911882

RESUMO

OBJECTIVE: To assess the effect of the intraoperative application of the Aquamantys® system to treat the hepatic resection margin on local and overall recurrence of HCC. METHODS: We retrospectively analyzed 101 patients admitted from November 2016 to June 2018 who underwent hepatectomy using the Aquamantys® as hemostatic device, who were matched with 101 patients (control group) using conventional hemostatic devices through PSM. Univariate and multivariate analyses of recurrence-free survival (RFS) and local recurrence-free survival (LRFS) were performed using the Cox proportional hazard model. RESULTS: There were no significant differences in baseline data and surgical procedures between the two groups. The Aquamantys® group showed less blood loss (P = 0.005) and a lower blood transfusion rate (P = 0.036), while the incidences of postoperative complications of the two groups showed no difference (P = 0.266). OS rates of the Aquamantys® group and the control group were 82.6% and 84.2%, respectively (P = 0. 446), and RFS rates were 65.5% and 58.2%, respectively (P = 0.153), with no significant differences. The Aquamantys® group and the control group had two cases and 11 cases of local recurrence, respectively, with LRFS rates of 98% and 87.9%, respectively, in the follow-up period, corresponding to a significant difference (P = 0.011). Multivariate analysis showed that microvascular invasion (MVI), tumor diameter > 5 cm, and the control group were independent risk factors for LRFS. CONCLUSION: Our results indicate that application of the Aquamantys® system in hepatectomy can reduce local recurrence, but it can neither reduce overall recurrence nor improve OS.


Assuntos
Carcinoma Hepatocelular/cirurgia , Eletrocirurgia/instrumentação , Hemostasia Cirúrgica/instrumentação , Hepatectomia , Neoplasias Hepáticas/cirurgia , Recidiva Local de Neoplasia , Perda Sanguínea Cirúrgica/prevenção & controle , Transfusão de Sangue/estatística & dados numéricos , Carcinoma Hepatocelular/prevenção & controle , Estudos de Casos e Controles , Intervalo Livre de Doença , Feminino , Hemostasia Cirúrgica/métodos , Humanos , Neoplasias Hepáticas/prevenção & controle , Masculino , Margens de Excisão , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/prevenção & controle , Pontuação de Propensão , Modelos de Riscos Proporcionais , Análise de Regressão , Estudos Retrospectivos
2.
Genet Mol Res ; 14(4): 13203-7, 2015 Oct 27.
Artigo em Inglês | MEDLINE | ID: mdl-26535633

RESUMO

The aim of this study was to investigate the expression of CD44 and its clinical significance in children suffering from hepatoblastoma (HB). CD44 expression was detected with immunohistochemistry staining in 30 samples from hepatoblastoma children and 10 normal liver tissue samples from normal children. The data obtained was statistically analyzed using the chi-square test, using the SPSS (v.11.0) software. The rate of CD44 expression was significantly higher (66.7%) in hepatoblastoma tissues than in normal liver tissues (χ(2) = 4.848, P < 0.05). The rate of CD44 expression was significantly higher in children with stage III or IV hepatoblastoma (83.3%) than that in children with stage I and II hepatoblastoma (χ(2) = 5.625, P < 0.05) (41.7%). Therefore, CD44 expression might play an important role in the pathogenesis, progression, and prognosis of HB in children.


Assuntos
Hepatoblastoma/metabolismo , Hepatoblastoma/patologia , Receptores de Hialuronatos/metabolismo , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patologia , Criança , Progressão da Doença , Feminino , Expressão Gênica , Hepatoblastoma/genética , Humanos , Receptores de Hialuronatos/genética , Imuno-Histoquímica , Neoplasias Hepáticas/genética , Masculino , Estadiamento de Neoplasias , Prognóstico
3.
Genet Mol Res ; 13(1): 499-507, 2014 Jan 21.
Artigo em Inglês | MEDLINE | ID: mdl-24535878

RESUMO

The aim of this study was to investigate the expression of glycosylphosphatidylinositol anchor attachment protein 1 (GPAA1) and its significance in patients with colorectal cancer. Fifty-two patients with primary colorectal cancer were included in this study. GPAA1 expression was detected by immunohistochemistry, reverse transcription-polymerase chain reaction, and Western blot analysis. A cell invasion assay was performed by the transwell method. The interacting proteins of GPAA1 were detected by co-immunoprecipitation and matrix assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/TOF-MS). The expression of GPAA1 mRNA and protein in primary colorectal tumor tissues and liver metastasis tissues was significantly higher than that in normal mucosa tissues (P < 0.01). The number of highly expressing GPAA1 cells penetrating the Matrigel membrane was significantly higher than that of mildly expressing GPAA1 cells (P < 0.05). The results of co-immunoprecipitation and MALDI-TOF/TOF-MS confirmed the identity of the protein. GPAA1 is highly expressed in patients with colorectal cancer, which indicates that it might play an important role in the proliferation, invasion, and metastasis of colorectal cancer.


Assuntos
Neoplasias Colorretais/metabolismo , Glicoproteínas de Membrana/metabolismo , Neoplasias Colorretais/diagnóstico , Humanos , Glicoproteínas de Membrana/genética , Pessoa de Meia-Idade , Ligação Proteica , RNA Mensageiro/genética , RNA Mensageiro/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA